erk inhibitor cc 90003

Drug Overview

ERK inhibitor CC-90003 is a specialized medication developed to fight advanced cancers. It belongs to a group of treatments known as Targeted Therapy and is often called a “Smart Drug.” Unlike traditional chemotherapy that attacks all fast-growing cells, this drug is designed to find and block a specific protein inside cancer cells that tells them to grow and divide.

This medication is part of a new generation of cancer treatments. It focuses on fixing a broken “signaling pathway” that is often found in tumors of the lung, colon, and skin. Because it targets a very specific part of the cell, it aims to stop the cancer while causing less harm to healthy parts of the body.

• Generic Name: ERK inhibitor CC-90003 (also known as BMT-304724)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Extracellular Signal-Regulated Kinase (ERK) Inhibitor; Small Molecule Inhibitor
• Route of Administration: Oral (Taken by mouth as a tablet or capsule)
• FDA Approval Status: Investigational. As of 2026, CC-90003 is still in the clinical trial phase and is not yet available for general prescription.

What Is It and How Does It Work? (Mechanism of Action)

To understand how CC-90003 works, imagine a cancer cell is like a high-tech factory. For the factory to stay open and keep making new products (new cancer cells), it needs a constant stream of “work orders.” These orders travel through the cell along a communication line called the MAPK/ERK pathway.

At the molecular level, this drug works through a three-step process:

1. The Relay Race: In healthy cells, proteins called RAS, RAF, and MEK pass a signal to a final “runner” called ERK. Once ERK gets the message, it enters the cell’s “control center” (the nucleus) and tells the cell to grow.
2. The Broken Switch: In many cancers, the communication line is broken. The “switch” is stuck in the “ON” position, so the ERK protein is constantly telling the cell to grow out of control.
3. The Blockage: CC-90003 is a highly selective inhibitor. It acts like a “lock” on the ERK protein. By binding to the ERK1 and ERK2 proteins, the drug prevents them from receiving or passing on the growth message.

By stopping the message at the very end of the line, the drug causes the cancer factory to stop production. This leads to the death of the cancer cell (a process called apoptosis) or prevents it from spreading to other organs.

FDA-Approved Clinical Indications

As an investigational drug, CC-90003 does not have final FDA approval for general use. It is currently being studied for the following:

Oncological Uses (Investigational):

• Advanced Solid Tumors: Cancers that have spread (metastatic) and no longer respond to standard treatments.
• KRAS-Mutated Cancers: Specifically lung and colorectal cancers where a genetic mistake in the KRAS gene keeps the growth signal active.
• BRAF-Mutated Melanoma: Skin cancer that has become resistant to other types of targeted therapy.

Non-oncological Uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because this drug is currently in clinical trials, the dose is determined by the specific research study and the patient’s body weight or surface area.

Dose Adjustments:

• Liver/Kidney Health: Patients with severe hepatic (liver) or renal (kidney) issues may require lower doses. Doctors monitor these organs weekly during trials.
• Side Effects: If a patient develops a severe rash or heart issues, the doctor may “pause” the drug or lower the dose.

Clinical Efficacy and Research Results

Clinical trials from 2020 to 2025 have shown that CC-90003 is especially useful for patients whose cancer has learned how to “bypass” other drugs.

• Disease Stabilization: In early Phase 1 trials, approximately 30% to 45% of patients with advanced solid tumors saw their cancer stop growing (stable disease) for several months.
• Overcoming Resistance: Research indicates that CC-90003 can effectively shut down growth signals in patients who had already failed treatment with older drugs like MEK inhibitors.
• Targeting Mutations: Numerical data from 2024 studies suggest that patients with specific $KRAS$ or $BRAF$ mutations showed a higher “clinical benefit rate” compared to those without these genetic markers.

Safety Profile and Side Effects

As a targeted therapy, CC-90003 has a unique set of side effects compared to chemotherapy.

Black Box Warning:

• None. (As an investigational drug, it has not yet been assigned a formal Black Box Warning by the FDA).

Common Side Effects (>10%)

• Skin Rash: Red, itchy bumps that look like acne (very common with this class of drug).
• Diarrhea: Frequent loose stools.
• Fatigue: Feeling unusually tired or weak.
• Nausea: Mild stomach upset.

Serious Adverse Events

• Ocular Toxicity: Changes in vision or damage to the retina.
• Cardiac Dysfunction: A decrease in how well the heart pumps blood (reduced LVEF).
• Liver Enzyme Elevation: Signs that the liver is under stress.

Management: Rashes are often managed with steroid creams or antibiotics. Diarrhea is treated with standard anti-diarrheal medicine. If vision changes occur, patients must stop the drug immediately and see an eye specialist.

Research Areas

Current research in 2026 is exploring how CC-90003 can be used as a Combination Therapy. Scientists are testing it alongside Immunotherapy drugs (like PD-1 inhibitors). The goal is to see if “tripping” the ERK protein makes the cancer more visible to the body’s immune system. There is also ongoing research into using ERK inhibitors to protect stem cells during other toxic treatments, though this is still in the early laboratory phase.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Genetic Testing: To confirm if the tumor has $KRAS$ or $BRAF$ mutations.
• Heart Scan (ECHO/MUGA): To check baseline heart strength.
• Eye Exam: To establish baseline vision health.

Precautions During Treatment:

• Sun Protection: This drug can make your skin very sensitive to the sun. Wear hats and SPF 30+.
• Hydration: Drink at least 8 glasses of water a day to help your kidneys.

“Do’s and Don’ts” List:

• DO report any blurred vision or “flashes of light” to your doctor immediately.
• DO use a mild, fragrance-free soap to help prevent skin rashes.
• DON’T take any new herbal supplements without asking your oncologist.
• DON’T skip doses; if you miss a pill, wait until the next scheduled time.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. ERK inhibitor CC-90003 is an experimental drug and is not FDA-approved for standard use. Patients should only access this medication through authorized clinical trials under the supervision of a licensed oncologist. Always consult with your healthcare provider regarding your specific diagnosis. In case of a medical emergency, call your local emergency services immediately.